BluePrint Orphan
  • About
    • Team
    • Development Blog
    • White Papers
    • Contact Us
  • Services
    • Market Access and Forecasting
    • Data Management and Analytics
    • Global Pricing and Reimbursement
    • HEOR
    • Marketing and Messaging Analytics
    • Stakeholder Advisory Boards
  • Products
    • Indications
    • Therapeutics
  • BUSINESS DEVELOPMENT
    • RareValue >
      • RareValue Example
    • Out-License
    • On-Site Workshop


PERSPECTIVES ON BIOPHARMA TRENDS

Therapeutic Development: Ganaxolone (CCD-1042)

6/11/2015

 
Updated: November 10, 2016
Ganaxolone is a GABA modulator currently being investigated by Marinus Pharmaceuticals. Clinical trials are currently underway to evaluate ganaxolone in the treatment of pediatric genetic orphan epilepsies, behaviors in Fragile X Syndrome, and status epilepticus.
Inquire About Specific Indication

Read More

    Archives

    May 2020
    February 2019
    May 2018
    January 2017
    December 2016
    November 2016
    March 2016
    November 2015
    September 2015
    June 2015
    December 2014

    Topics

    All
    Business Development
    Gene Therapy
    Licensing
    Ophthalmic Therapy
    Rare Disease
    Regenerative Therapy
    Small Molecule
    Stem Cell Therapy
    Therapeutic Development

Home

Team

Products

Business Development

Contact

info@blueprintorphan.com
  • About
    • Team
    • Development Blog
    • White Papers
    • Contact Us
  • Services
    • Market Access and Forecasting
    • Data Management and Analytics
    • Global Pricing and Reimbursement
    • HEOR
    • Marketing and Messaging Analytics
    • Stakeholder Advisory Boards
  • Products
    • Indications
    • Therapeutics
  • BUSINESS DEVELOPMENT
    • RareValue >
      • RareValue Example
    • Out-License
    • On-Site Workshop